Zealand Pharma's Weight-Loss Drug Trial Fails Due to Side Effects
Shares of Zealand Pharma dropped nearly 23% after a late-stage trial of its weight-loss drug Servodutide showed high dropout rates due to adverse effects. This is seen as positive news for Eli Lilly and Novo Nordisk, which dominate the GLP-1 space.
Topics: Biotech GLP-1 Agonists Phase III Trials Weight Loss Drugs